Novo Nordisk said it will lower list prices for its GLP‑1 medicines to $675 per month beginning in 2027 and concurrently reported midstage triple‑agonist weight‑loss data, as the company grapples with mounting competitive pressure from Eli Lilly. The pricing move targets patients with high deductibles and follows public and political scrutiny of obesity drug costs. The pricing announcement comes amid fresh data showing Novo’s next‑generation combination candidate CagriSema failed to demonstrate non‑inferiority to Lilly’s Zepbound in a head‑to‑head Phase 3 study, a result that trimmed Novo’s market valuation and intensified the pricing and positioning battle between the two leaders. Novo framed the measures as efforts to improve access while advancing next‑generation assets; analysts warned the pricing concession and trial miss could further compress margins and accelerate market share shifts toward competitors with superior head‑to‑head efficacy.